Empagliflozin
SGLT2 Inhibitor- Drug Class
- SGLT2 Inhibitor
- Mechanism of Action (MOA)
- Blocks SGLT2 in the proximal tubule → glucosuria (insulin-independent).
- Clinical Notes
- T2DM with cardiovascular/renal/HF benefit (now used in HFrEF and CKD even without diabetes). Genital mycotic infections, euglycemic DKA, volume depletion.
- Source
- FDA label
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
Used for
Same family
Got a pharmacology lecture that covers Empagliflozin? Turn it into flashcards and board-style questions, free. Drop it on the home page
All pharmacology